1Biragyn A,Belyakov IM,Chow YH,et al.DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses[J].Blood,2002,100(4):1153
2Neshat MN,Coodglick L,Lim K,et al.Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig[J].Int Immunol,2000,12(3):305
3Boyd MR,Gustafson KR,McMahon JB,et al.Discovery of cyanovirin-N,anovel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120:potential applications to microbicide development[J].Antimicrob,Agents Chemother,1997,41(7):1521
4Han Z,Simpson JT,Fivash MJ,et al.Identification and characterization of peptides that bind to cyanovirinN,a potent human immunodeficiency virus-inactivating protein[J].Peptides,2004,25(4):551
5Bolmstedt AJ,OKeefe BR,Shenoy SR,et al.Cyanovirin-N Defines a New Class of Antiviral Agent Targeting N-Linked,High-Mannose Glycans in an Oligosaccharide-Specific Manner[J].Mol Pharmacol,2001,59(5):949
6Tsai CC,Emau P,Jiang Y,et al.Cyanovirin-N Gel as a Topical Microbicide Prevents Rectal Transmission of SHIV89.6P in Macaques[J].AIDS Research and Human Retroviruses,2004,20(1):11
7Chen B,Vogan,EM,Vogan,HY et al.Structure of an unliganded simian immunodeficiency virus gp120 core[J].Nature,2005,433(7028):834
1Weiss R A. Gulliver's travels in HIVl and. Nature, 2001, 410: 963-967
2Stevenson M. HIV-1 Pathogenesis. Nature Med, 2003, 9: 853-860
3Cormier E G, Tran D N, Yukhayeva L, et al. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol, 2001, 75: 5541～5549
4Zhang W T, Canziani G, Plugariu C, et al. Conformation changes of gp120 in epitopes near the CCR5 binding site are induce by CD4 and a CD4 miniprotein mimetic. Biochemistry, 1999, 38: 9405～9416
5Kwong P D, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 1998, 393: 648～659
6Wyatt R, Kwong P D, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature, 1998, 393: 705～711
7Field C G, Lloyd D H, Macdonaid R L, et al. HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res, 1991, 4: 95～101
8Tsamis F, Gavrilov S, Kajumo F, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol, 2003, 77: 5201～5208
9Hoffmann C, Kamps B S. HIV Medicine. Paris: Flying Publisher, 2003
10Wood E,Hogg RS,Yip B,et al.Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0. 200 to 0. 350 x 109 cells/L[].Annals of Internal Medicine.2003
5UNAIDS/WHO. AIDS epidemic update: December 2005 [ M ]. 2005.
6Narain JP, Lo Y R. Epidemiology of HIV-TB in Asia[ J ]. Indian J Med Res,2004,120 (4) :277 -289.
7Sharma SK, Mohan A, KadhiravanT. HIV-TB co-infection : pidemiology,diagnosis and management[ J]. Indian J Med Res,2005,121(4) :550-567.
8Cooley L A, Lewin S R. HIV-1 cell entry and advances in viral entry inhibitor therapy[ J]. J Clin Virol,2003, (26) :121.
9PuglieseA, VidottoV, Beltramo T, et al. Phagocytic Activity in Human Immuno deficiency Virus Type 1 Infection[ J]. Clin and DiagLab Immuno,2005,12 ( 8 ) : 889-895.
10Huang Y, Erdmann N, Peng H, et al. TRAIL-Mediated Apoptosis in HIV-l-infected Macrophages Is Dependent on the Inhibition of Akt-1 Phosphory-lation [ J ]. J Immuno1,2006,177 (4) :2304-2313.
